Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Myelosuppression“
Suchtreffer
Begriffe & Kennungen
Onivyde pegylated liposomal (previously Onivyde) · 4.8 · ONIVYDE pegylated liposomal in combination with 5-fluorouracil and leucovorin: Myelosuppression (neutropenia/l
Eintrag öffnenPluvicto · 4.8 · Myelosuppression In the VISION study, myelosuppression occurred more frequently in patients who received Pluvi
Eintrag öffnenPluvicto · 4.8 · Myelosuppression adverse reactions that led to permanent discontinuation in ≥0.5% of patients who received Plu
Eintrag öffnenPolivy · 4.8 · Myelosuppression In a placebo-controlled study GO39942 (POLARIX), 0.5% of patients in the Polivy plus R-CHP ar
Eintrag öffnenScemblix · 4.8 · Myelosuppression Thrombocytopenia occurred in 28.1% of patients receiving asciminib, with grade 3 and 4 reacti
Eintrag öffnenSiklos · 4.3 · Toxic ranges of myelosuppression as described in section 4.2.
Eintrag öffnenSpectrila · 4.5 · During treatment with asparaginase-containing regimens, myelosuppression, potentially affecting all three myel
Eintrag öffnenSprycel · 4.8 · 15 Description of selected adverse reactions Myelosuppression Treatment with SPRYCEL is associated with anaemi
Eintrag öffnenSprycel · 4.8 · 51 Description of selected adverse reactions Myelosuppression Treatment with SPRYCEL is associated with anaemi
Eintrag öffnenTalzenna · 4.8 · In monotherapy studies (1 mg/day population), the most frequent myelosuppression-related adverse events associ
Eintrag öffnenTalzenna · 4.8 · Myelosuppression Myelosuppression-related adverse reactions of anaemia, neutropenia and thrombocytopenia were
Eintrag öffnenTemodal · 4.3 · Severe myelosuppression (see section 4.4).
Eintrag öffnenTemodal · 4.3 · Severe myelosuppression (see section 4.4).
Eintrag öffnenTemodal · 4.5 · Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.
Eintrag öffnenTemodal · 4.5 · Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.
Eintrag öffnenTemodal · 4.8 · Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic
Eintrag öffnenTemodal · 4.8 · Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic
Eintrag öffnenTemomedac · 4.3 · Severe myelosuppression (see section 4.4).
Eintrag öffnenTemomedac · 4.5 · Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.
Eintrag öffnenTemomedac · 4.8 · Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic
Eintrag öffnen